AR and posterior cortical atrophy: In most cases, PCa is an AR-dependent tumor; thus, androgen deprivation therapy (ADT) and AR signaling inhibition (ARSI) therapy persist as the mainstay systemic therapies for patients with recurrent or metastatic PCa [5,6,7].